Mark Winderlich

2.1k total citations
25 papers, 1.6k citations indexed

About

Mark Winderlich is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Mark Winderlich has authored 25 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pathology and Forensic Medicine and 10 papers in Genetics. Recurrent topics in Mark Winderlich's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (10 papers). Mark Winderlich is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (10 papers). Mark Winderlich collaborates with scholars based in Germany, United States and Italy. Mark Winderlich's co-authors include Astrid F. Nottebaum, Dietmar Vestweber, Giuseppe Cagna, Urban Deutsch, Alexander Zarbock, Maike Frye, Andre Broermann, Olena Kamenyeva, Gou Young Koh and Pipsa Saharinen and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Mark Winderlich

23 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Winderlich Germany 12 896 354 352 285 253 25 1.6k
Jackelyn A. Alva United States 10 1.6k 1.7× 343 1.0× 358 1.0× 157 0.6× 404 1.6× 13 2.4k
Astrid F. Nottebaum Germany 15 1.1k 1.3× 219 0.6× 425 1.2× 368 1.3× 320 1.3× 23 1.8k
Marian A. J. Weterman Netherlands 27 1.3k 1.4× 342 1.0× 203 0.6× 196 0.7× 311 1.2× 45 2.1k
Anika Stadtmann Germany 14 510 0.6× 203 0.6× 749 2.1× 431 1.5× 153 0.6× 16 1.5k
Thomas N. Sato United States 12 1.2k 1.4× 248 0.7× 159 0.5× 139 0.5× 289 1.1× 17 1.8k
Michael I. Dorrell United States 25 1.7k 1.9× 192 0.5× 238 0.7× 111 0.4× 251 1.0× 32 2.9k
Angelina Felici Italy 21 1.3k 1.4× 486 1.4× 225 0.6× 98 0.3× 225 0.9× 39 2.4k
Brian G. Coon United States 18 1.1k 1.2× 246 0.7× 184 0.5× 208 0.7× 709 2.8× 28 2.1k
Fumiko Itoh Japan 26 2.2k 2.4× 559 1.6× 215 0.6× 141 0.5× 246 1.0× 56 3.0k
Lucia Zanetta Italy 12 1.1k 1.2× 269 0.8× 260 0.7× 182 0.6× 531 2.1× 15 1.9k

Countries citing papers authored by Mark Winderlich

Since Specialization
Citations

This map shows the geographic impact of Mark Winderlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Winderlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Winderlich more than expected).

Fields of papers citing papers by Mark Winderlich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Winderlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Winderlich. The network helps show where Mark Winderlich may publish in the future.

Co-authorship network of co-authors of Mark Winderlich

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Winderlich. A scholar is included among the top collaborators of Mark Winderlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Winderlich. Mark Winderlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Nowakowski, Grzegorz S., Dok Hyun Yoon, Anthea Peters, et al.. (2022). Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research. 28(18). 4003–4017. 16 indexed citations
3.
4.
5.
Raab, Marc S., Monika Engelhardt, Antje Blank, et al.. (2020). MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial. The Lancet Haematology. 7(5). e381–e394. 68 indexed citations
6.
7.
Jurczak, Wojciech, Pier Luigi Zinzani, Gianluca Gaïdano, et al.. (2018). Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Annals of Oncology. 29(5). 1266–1272. 101 indexed citations
8.
Nowakowski, Grzegorz S., David Belada, Kateřina Kopečková, et al.. (2017). B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase II/III trial.. Journal of Clinical Oncology. 35(15_suppl). TPS7571–TPS7571. 2 indexed citations
9.
Chatterjee, Manik, Marc S. Raab, Hartmut Goldschmidt, et al.. (2017). A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 17(1). e61–e61. 20 indexed citations
10.
Jurczak, Wojciech, Pier Luigi Zinzani, Gianluca Gaïdano, et al.. (2016). Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. Blood. 128(22). 623–623. 6 indexed citations
11.
Jurczak, Wojciech, Pier Luigi Zinzani, André Goy, et al.. (2015). Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).. Journal of Clinical Oncology. 33(15_suppl). 8500–8500. 3 indexed citations
12.
Wessel, Florian, Mark Winderlich, Maike Frye, et al.. (2014). Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin. Nature Immunology. 15(3). 223–230. 274 indexed citations
13.
14.
Winderlich, Mark, Daniel Ness, Stefan Steidl, & Jan Endell. (2012). Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma.. Journal of Clinical Oncology. 30(15_suppl). 6574–6574. 3 indexed citations
15.
Broermann, Andre, Mark Winderlich, Helena Block, et al.. (2011). Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. The Journal of Experimental Medicine. 208(12). 2393–2401. 157 indexed citations
16.
Broermann, Andre, Mark Winderlich, Helena Block, et al.. (2011). Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. The Journal of Cell Biology. 195(3). i4–i4. 2 indexed citations
17.
Winderlich, Mark, Giuseppe Cagna, Andre Broermann, et al.. (2009). VE-PTP controls blood vessel development by balancing Tie-2 activity. The Journal of Cell Biology. 185(4). 657–671. 146 indexed citations
18.
Nottebaum, Astrid F., Giuseppe Cagna, Mark Winderlich, et al.. (2008). VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. The Journal of Experimental Medicine. 205(12). 2929–2945. 184 indexed citations
19.
Saharinen, Pipsa, Lauri Eklund, Juho J. Miettinen, et al.. (2008). Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts. Nature Cell Biology. 10(5). 527–537. 352 indexed citations
20.
Vestweber, Dietmar, Mark Winderlich, Giuseppe Cagna, & Astrid F. Nottebaum. (2008). Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends in Cell Biology. 19(1). 8–15. 223 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jackelyn A. Alva Breakdown of academic impact, for papers by Astrid F. Nottebaum Breakdown of academic impact, for papers by Marian A. J. Weterman Breakdown of academic impact, for papers by Anika Stadtmann Breakdown of academic impact, for papers by Thomas N. Sato Breakdown of academic impact, for papers by Michael I. Dorrell Breakdown of academic impact, for papers by Angelina Felici Breakdown of academic impact, for papers by Brian G. Coon Breakdown of academic impact, for papers by Fumiko Itoh Breakdown of academic impact, for papers by Lucia Zanetta
Rankless by CCL
2026